6.84
-0.15(-2.15%)
Currency In USD
| Previous Close | 6.99 |
| Open | 6.79 |
| Day High | 7.09 |
| Day Low | 6.73 |
| 52-Week High | 18.62 |
| 52-Week Low | 6.61 |
| Volume | 535,356 |
| Average Volume | 376,745 |
| Market Cap | 404.07M |
| PE | -2.16 |
| EPS | -3.16 |
| Moving Average 50 Days | 7.68 |
| Moving Average 200 Days | 9.07 |
| Change | -0.15 |
If you invested $1000 in Cullinan Oncology, Inc. (CGEM) since IPO date, it would be worth $228.69 as of September 09, 2025 at a share price of $6.84. Whereas If you bought $1000 worth of Cullinan Oncology, Inc. (CGEM) shares 3 years ago, it would be worth $504.42 as of September 09, 2025 at a share price of $6.84.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
GlobeNewswire Inc.
Jun 04, 2025 8:02 PM GMT
Advances Cullinan’s leadership in T cell engager (TCE) development for autoimmune diseases with both a CD19 TCE and BCMA TCE in its pipeline Strengthens Cullinan portfolio of autoimmune programs with the opportunity to address a broader range of dise
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 11:00 AM GMT
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its management team will host a compa
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
GlobeNewswire Inc.
May 22, 2025 9:15 PM GMT
CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase